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Abstract Prostate cancer is (PCa) the second leading cause of cancer death in males in the
United State, with 174,650 new cases and 31,620 deaths estimated in 2019. It has been docu-
mented that epigenetic deregulation such as histone modification and DNA methylation con-
tributes to PCa initiation and progression. EZH2 (enhancer of zeste homolog 2), the catalytic
subunit of the Polycomb Repressive Complex (PRC2) responsible for H3K27me3 and gene
repression, has been identified as a promising target in PCa. In addition, overexpression of
other epigenetic regulators such as DNA methyltransferases (DNMT) is also observed in PCa.
These epigenetic regulators undergo extensive post-translational modifications, in particular,
phosphorylation. AKT, CDKs, PLK1, PKA, ATR and DNA-PK are the established kinases respon-
sible for phosphorylation of various epigenetic regulators.
Copyright ª 2019, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
While a majority of studies have demonstrated that accu-
mulation of genetic mutations will result in cancer initia-
tion and progression, epigenetic changes without altering
DNA sequences, which have been under intensive research
in recent years, also contribute to activation of oncogenes
and inactivation of tumor suppressors, and subsequently
leading to the development of cancer.1 Epigenetics is usu-
ally defined as a heritable change in gene expression
without alteration in DNA sequence, including three pri-
mary epigenetic mechanisms - DNA methylation, covalent
modification of histones and non-coding RNAs. It has been
noted that heritable epigenetic marks can be dynamically
regulated in response to any change in physiological con-
ditions. Therefore, failure of the appropriate maintenance
of these marks will highly possibly result in disease states
such as cancer.2 Epigenetic modifiers refer to adding or
removing DNA methylation or histone modifications, which
are defined as writers or erasers respectively. Besides
writers and erasers, some epigenetic effectors can also be
recruited, and affect the final epigenetic programs which
we call them “readers”. Increasing data has shown that the
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activity of these epigenetic modifiers are also under regu-
lation of some posttranslational modifications, such as
phosphorylation, which might determine the final biological
outcome.3 In this review, we will take a comprehensive look
of current findings of the regulation of the epigenetic
modifiers by phosphorylation during carcinogenesis. We will
also further discuss phosphorylation of one critical
“writer”- enhancer of zeste homolog 2 (EZH2), which is a
histone methyltransferase mainly mediating tri-
methylation of histone H3 at Lys 27 (H3K27me3), in pros-
tate cancer, and the idea of therapeutic strategies based on
EZH2 phosphorylation in prostate cancer treatment.
Epigenetic modification in cancer
DNA methylation aberrations have been firstly and mostly
linked to cancer initiation and progression among the
epigenetic alterations, which is featured with genome-wide
hypomethylation and hypermethylation of clusters of CpGs,
known as CpG islands.4 The role of global DNA hypo-
methylation in tumorigenesis has been well established. It
occurs in various cancers and becomes an important reason
resulting in increased genomic instability and inappropriate
activation of oncogenes.5 Hypermethylation of CpG islands
in the promoters of tumor suppressor genes to silence their
expressions has been well noted to contribute to tumori-
genesis. Many tumor suppressor genes, which are usually
involved in various tumor-associated cellular processes
including DNA repair, cell cycle, apoptosis, etc., have been
observed to undergo CpG island hypermethylation. These
genes, such as cell cycle related gene RB, the DNA repair
protein BRCA1, and the tumor suppressor p53, are observed
in different types of cancer like esophageal cancer, colo-
rectal and gastric cancers, in which they are commonly
mutated.6e9
DNA methylation is maintained by a family of enzymes
which are called DNA methyltransferases (DNMTs). There
are four members of the DNMT family, including DNMT1,
DNMT3A, DNMT3B and DNMT3L. Among them, DNMT1 plays
the main role in maintaining the methylation status of DNA;
at the same time, DNMT3A and DNMT3B are known to
encode the de novo methyltransferases which will meth-
ylate the unmethylated DNA, while DNMT3L, unlike the
other DNMTs, has no enzymatic activity.10 A number of
studies have demonstrated a relationship between alter-
ations of DNMTs and tumorigenesis. Overexpression of
DNMTs has been well reported in a variety of human cancers
via correlating with aberrant DNA methylation. Conse-
quently, overexpression of DNMTs tends to result in
increased metastasis and poor prognosis. Highly expressed
DNMT1 has been found in numerous patient specimens such
as esophageal squamous cell carcinoma and pancreatic
cancer. Similarly, increased DNMT3A or DNMT3B is involved
in liver cancer, BRCA1-mutated breast tumor, intestinal
neoplasia and prostate tumors.11e17 In addition to over-
expression of DNMTs, somatic mutations in DNMTs are also
reported as an important contributor to malignant trans-
formation. These mutations have been observed in colon
cancers or acute myeloid leukemia, thus leading to
disruption of normal DNA methylation and subsequently
tumor promotion.18e20 While deletion of DNMTs in mouse
models has shown a lethal phenotype, several recent
studies based on the conditional knockout approach
demonstrated that loss of DNMTs also participates in
development of peripheral T cell lymphoma (PTCL) or
AML.21e23
The N-terminal tails of histones, in which lysine and
arginine residues are distributed, are subject to a variety of
covalent posttranslational modifications (PTMs), such as
acetylation, phosphorylation and methylation.24 PTMs of
proteins are highly dynamic in response to the altered
contexts to ensure the histone modification in balance
which is critical for maintaining genome integrity.25 Many
different combinations of PTMs on multiple residues, which
defined as “histone code” and regulated by enzymes as
“writers” and “erasers”, can precisely govern specific
cellular responses, such as cell cycle or signal
transductions.26,27
Misregulation of histone PTMs, including acetylation,
methylation and phosphorylation, have been extensively
linked to a variety of cancer types.28 In tumors, such a
misregulation results in the abnormal activation of onco-
genes or the repression of tumor suppressors. And the
PTMs-induced inappropriate activation or inactivation de-
pends on which residues are modified and which type of
modifications occur.29 Generally speaking, lysine acetyla-
tion can open up chromatin structure and subsequently
tend to activate the transcription of its target genes.24
Therefore, histone acetyltransferase (HATs) should pro-
mote transcription whereas histone deacetylases (HDACs)
should be anti-transcriptional. Alterations and mutations
occur on HATs (e.g. MOZ or CBP/EP300) or HDACs have
been reported to correlate with a poor clinical outcome in
cancer patients.30e32 Besides the histone acetylation
“writers” HATs or “erasers” HDACs, the histone acetylation
“readers” the BET (bromodomain and extraterminal
domain) proteins, such as BRD4, show increased expression
in a variety of cancers. Consequently, the BET inhibitors,
like JQ1, have demonstrated great therapeutic efficacy for
the treatment of cancers, such as leukemia.33,34 Unlike
histone acetylation, histone methylation will not exclu-
sively act as a transcriptional activator or repressor; the
activation or inactivation depends upon the open or close
of the chromatin structure arising from which residue is
modified and the degree of its methylation.35 Similar with
histone acetylation, tumor cells are also found common
alterations of histone methylation and its histone meth-
yltransferases (HMTs). For example, H3K27 trimethylation
contributes to the aberrant silencing of multiple tumor
suppressor genes and is associated with poor diagnosis of
patients, and correspondingly, its main HMT, EZH2, is
overexpressed in these cancers such as prostate cancer
and breast cancer.36 Similarly, the dysregulation of other
HMTs and the methylation patterns (e.g. G9a and
H3K9me3), have been found in cancers as well.37 Histone
demethylases have been recently identified to have a
linkage to cancer. For example, LSD1, the demethylase for
H3K4 and H3K9 residues, has been found overexpressed in
many types of cancer.38 Histone phosphorylation is a dy-
namic process catalyzed by several distinct kinases that
are depending on different amino acid residues in his-
tone.39 Histone phosphorylation occurs with the change of
many cellular processes, such as cell cycle, DNA damage
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repair, and apoptosis, therefore its misregulation often
leads to tumorigenesis. Accordingly, the kinases regulating
the histone phosphorylation are always found overex-
pressed in cancers. For example, high PRK1 level, which
mediates H3T11 phosphorylation, correlates with high
stages of prostate cancer.40
Noncoding RNAs (ncRNAs) has also been regarded as a
crucial epigenetic modification gaining intensive attention.
With technical development, many types of ncRNAs have
been identified, including microRNAs (miRNAs), PIWI-
interacting RNAs (piRNAs), small nucleolar RNAs (snoR-
NAs), the complicated long ncRNAs (lncRNAs), and the
newly validated circular RNAs (circRNAs), etc.41 Increasing
evidence has shown that ncRNAs are of essential impor-
tance for the development of human diseases notably
cancers via their crucial regulatory potency in gene
expression at the transcriptional, post-transcriptional, or
translational processes. Among them, the most deeply
studied miRNAs and lncRNAs, aberrantly expressed in a
variety of cancers, play oncogenic or tumor suppressive
functions in these processes.42,43
As a post-transcriptional regulator of gene expression,
miRNAs have been extensively believed abnormally
expressed in tumors. The dysregulation of miRNAs would
affect several cancer hallmarks for tumor initiation and
progression which include sustaining cell cycle and prolif-
erative signaling, avoiding from cell death, and intriguing
invasion and metastasis.44 Cell-cycle regulation is highly
rely on cyclins, cyclin-dependent kinases (CDKs) and their
inhibitors. In a variety of human tumors, the CDK inhibitor
p27Kip1, p21CIP1 and p16INK4a have been found to be
directly regulated by miRNAs such as miR-221/222 miR-
663, miR-302 and miR-24 which are highly upregulated in
tumors.45e47 In addition, miRNAs can also regulate
expression of CDKs and cyclin not just inhibitors. Cyclin D1
and CDK4 are repressed by miRNA-545 leading to cell-cycle
arrest in lung cancer.48 MiRNAs have been known to take
part in resisting apoptosis. Dysregulation of several miRNAs
involved in p53 functions, such as miR-17e92, has been
identified and confers tumor cells resistant to
chemotherapy-induced cell death.49 It has also been
shown that miRNAs are fully involved in cancer metastasis.
For example, a number of TGF-b-associated miRNAs, such
as miR-155, engage in the process of TGF-b-induced
epithelialemesenchymal transition (EMT) which have been
widely accepted as a key step in the cancer
metastasis.50,51
Similar with miRNAs, increasing research has revealed
lnRNAs playing an emerging role in tumor suppression or
oncogenesis in recent years. It has been well demonstrated
that aberrant lncRNAs affect cancer cell proliferation and
metastasis by remodeling chromatin structure and regu-
lating oncogenes or tumor suppressors transcriptionally and
post-transcriptionally.52 A good example of lncRNAs medi-
ating epigenetic modifications is the HOX antisense inter-
genic RNA (HOTAIR) which has been applied as a predictive
marker for metastasis in a variety of cancer, such as breast
cancer.53 HOTAIR working with the chromatin-modifying
complexes PRC2 which catalyzes H3K27 trimethylation,
affects the transcription of target genes via a PCR2-lnRNA
binding.54 Besides influencing PRC2 enzymatic function,
HOTAIR can also enhance PLK1-mediated proteasomal
degradation of SUZ12 which is a core component of PRC2
complex during hepatitis B virus-induced liver
carcinogenesis.55
Phosphorylation of epigenetic modifiers in
cancer
Epigenetic modifiers, including “writers”, “erasers” and
“readers”, play a crucial role in maintaining the dynamic
balance of epigenetic modification patterns, usually
depending on their activities. It has been well established
that these modifiers are also under regulation of post-
translational modifications (PTMs), and their activity are
affected by these PTMs consequently.3 Among the PTMs,
the importance of phosphorylation contributing to epige-
netic events in response to environmental changes has been
widespread accepted. These phosphorylation is catalyzed
and mediated by many kinases including protein kinase B
(PKB/Akt), cyclin-dependent kinases (CDKs), polo-like ki-
nase 1(PLK1), protein kinase A (PKA), AMP-activated pro-
tein kinase (AMPK), casein kinase 2 (Ck2) and ataxia
telangiectasia and Rad3 related kinase (ATR), etc.
Phosphorylation-mediated regulation of modifiers may
directly activate or suppress their enzymatic activity, or
indirectly regulate the interaction between modifiers with
other proteins or RNAs, or make chromatin structure tight
or loose.56 And several epigenetic modifiers have been
found either aberrantly hyperphosphorylated or hypo-
phosphorylated in cancer cells, including DNA methyl-
transferases, histone methyltransferases, histone
demethylases, histone acetyltransferases and
deacetylases.
DNMTs especially DNMT1 have been known to be phos-
phorylated to regulate the protein stability and enzymatic
activity. AKT and PKC kinases were reported to phosphor-
ylate DNMT1 at Ser127/143 and Ser127, respectively, which
will disrupt the interactions of DNMT1 with PCNA and
UHRF1 in human cells to promote tumorigenesis.57,58 In
addition, it has been reported that GSK3b can interact with
DNMT1 and then phosphorylate DNMT1 at Ser410 and
Ser414, and finally promote bTrCP-induced proteasomal
degradation of DNMT1.59 There are not many reports
showing the phosphorylation of DNMT3s, however, the ki-
nase CK2 tends to phosphorylate DNMT3A, and decrease the
global genomic methylation levels.60
The histone methyltransferase EZH2 has been shown to
be phosphorylated by several kinases, such as AKT, AMPK,
CDKs, or Janus kinase 3 (JAK3), in various types of cancer.
AKT-mediated phosphorylation of EZH2 at Ser21 results in
loss of methylation of H3K27 and increase of expressions of
genes used to be silent by H3K27me3. The AKT-mediated
phosphorylation of EZH2 promotes expression of several
critical oncogenes, and is involved in the development of
prostate cancer, uterine cancer and glioblastoma tumor-
igenesis.61e63 AMPK can also phosphorylate EZH2 at Thr311
to disrupt the polycomb repressive complex 2 (PRC2), in
which EZH2 is the core component, and thus suppresses
methyltransferase activity in both ovarian and breast can-
cers.64 In addition, CDK1/2 have also been reported to
phosphorylate EZH2 at Thr350 and Thr487, which will not
only inhibit the enzymatic activity, but also block EZH2
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binding to its target region, and will highly increase the risk
of tumorigenesis.65,66 Phosphorylation of EZH2 by JAK3 in-
duces a noncanonical function of EZH2 to promote tran-
scriptional activation in natural killer/T-cell lymphoma.67
Collectively, regulation of EZH2 by phosphorylation is
highly correlated with tumorigenesis with regard to its ac-
tivity. We will further discuss about the role of EZH2 and its
phosphorylation in prostate cancer and castration-resistant
prostate cancer (CRPC) in the subsequent session.
Although contribution to cancer by the phosphorylation
of H3K27 histone methyltransferase has been extensively
studied, phosphorylation of histone methyltransferases
that add methyl groups to other residues of histone tail,
such as H3K4, was also reported. For instance, ATR phos-
phorylates MLL (H3K4 methyltransferase) on Ser516 in
response to environmental stress in the S phase, resulting in
its degradation and finally contributing to human MLL
leukaemia.68 Several studies also demonstrated the unusual
phosphorylation events occurring on arginine methyl-
transferases. For example, in myeloproliferative neo-
plasms, Janus kinase 2 (JAK2) oncogenic mutant V617F can
phosphorylate protein arginine methyltransferase 5
(PRMT5), consequently decreasing its activity and
increasing expression of genes that are inhibited by
PRMT5.69
Histone demethylases also appear to be regulated by
phosphorylation, although how phosphorylation affects the
activities still remains to be elucidated. Protein kinase A
(PKA)-induced phosphorylation of H3K9me2 demethylase
PHD finger protein 2 (PHF2) at Ser1056 results in its
increased binding to a DNA-binding protein ARID5B, reduc-
tion of methylation on ARID5B, and decrease of gene
transcription.70 CDK1 can catalyze phosphorylation of
another demethylase, PHD finger protein 8 (PHF8) at Ser33
and Ser84, leading to disruption of PHF8 with chromatin in
acute promyelocytic leukemia.71
Phosphorylation can also regulate the activities of HATs
and HDACs, and therefore affect the gene transcription via
histone acetylation patterns. The histone acetyltransferase
CBP is phosphorylated by CDK2 in a cell cycle-dependent
manner. One study demonstrated that the DNA-dependent
protein kinase (DNA-PK) phosphorylates hGCN5, which
possesses HAT activity, and the phosphorylation suppresses
its HAT activity.72 In addition, in response to DNA damage,
the HAT activity of activating transcription factor 2 (ATF2)
is phosphorylated.73 The PI3K/AKT pathway also stimulates
p300 phosphorylation at Ser1834 and its transcriptional
activator potential.74
Like HMTs, HDACs have been commonly believed that
their activities are tightly regulated by phosphorylation.
The HDAC family members, including HDAC1, HDAC2,
HDAC3, HDAC4, HDAC5, HDAC6 and HDAC8, are phosphor-
ylated by many kinases, such as CK2, PKA, extracellular
signal regulated kinase (ERK1/2), etc. within different
residues, to influence the structure, stability, acetyl-
transferase activity, binding with partners, or cellular
localization, and ultimately leading to either pro- or anti-
tumorigenesis.75,76 I will take two recent findings as ex-
amples. Activated PI3K/AKT pathway in breast cancer cells
can lead to the phosphorylation of the p70 S6 kinase (S6K1)
and transcriptionally regulate estrogen receptor a (ERa)
expression.77 Moreover, c-Jun N-terminal kinase (JNK)-
mediated phosphorylation of HDAC3 in triple-negative
breast cancer (TNBC) might affect the sensitivity of HDAC
inhibitors in treatment.78
EZH2 methyltransferase and its
phosphorylation in prostate cancer
In 2019, prostate cancer (PCa) has become the most com-
mon cancer with 174,650 newly diagnosed cases and the
second leading cause of death associated with cancer or
cancer-related factors in males in the United States with
estimated 31,620 deaths.79 Androgen deprivation therapy
(ADT) is the routinely used approach to treat PCa patients.
Although patients initially respond to ADT well, castration-
resistant prostate cancer (CRPC) eventually occurs in most
of these patients after several years and then develops into
even worse metastasis.80 It has been well established that
androgen receptor (AR) signaling is enhanced and plays an
important role in CRPC.81 Subsequently, the AR inhibitors,
such as enzalutamide and abiraterone, have been approved
by the Food and Drug Administration (FDA) for the treat-
ment of late stage PCa.82 However, enzalutamide resis-
tance eventually develops for almost all cases, making the
disease almost incurable. Therefore, how to overcome
enzalutamide resistance of CRPC has been under intensive
research, and new targets and mechanism-based strategies
are urgently needed to treat these patients.83e85
As we described above, EZH2, the catalytic subunit of
PRC2 complex, plays a critical role in repressing gene
expression by mediating H3K27me3. Many studies have
demonstrated that there is a tight linkage between EZH2
and oncogenesis, and that EZH2-mediated trimethylation
triggers silencing of tumor suppressor genes in cancer.86
Besides acting as a transcriptional suppressor, emerging
evidence has shown the uncanonical role of EZH2 towards
transcription activation of some genes, whose expression
seems to be PRC2-independent. EZH2 has been identified as
either a direct transcription activator or coactivator bind-
ing with other transcription factors to promote expression
of several oncogenes. For example, the transcription levels
of genes in NOTCH pathway, NF-kB pathway or Wnt
pathway are directly or indirectly regulated by EZH2 in
breast cancer and colon cancer, respectively, which are
independent of EZH2 methyltransferase activity87e90 (see
Fig. 1).
In PCa especially in CRPC, EZH2 is overexpressed and
promotes cancer cell proliferation and invasion, making
EZH2 an attractive anti-cancer drug target. Similar with
other types of cancer, aberrant PTMs, such as phosphory-
lation, of EZH2 are also found in PCa (Fig. 2). For example,
AKT-mediated phosphorylation of EZH2 at Ser21 induces a
functional switch from a PRC2-dependnet transcription
repressor to a PRC2-independent transcription coactivator
working with AR to promote the development of CRPC.61,63
In addition to AKT kinase, CDK1/2 can also phosphorylate
EZH2 at Thr350 during S and G2/M phases. Phosphorylation
of Thr350 promotes PCa cell proliferation and migration.
Consequently, blocking Thr350 phosphorylation is impor-
tant for abrogation of the oncogenic activity of EZH2.65,66
Polo-like kinase 1 (PLK1), a regulator of various stages of
mitosis, has been shown to be overexpressed in various
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types of cancers. Our lab has made a series of discoveries to
show that Plk1 plays a critical role in different aspects of
PCa, including its initiation, progression and therapy resis-
tance.91 It was shown that PLK1 directly phosphorylates
SUZ12, another component of PRC2 complex, and that PLK1
phosphorylation of SUZ12 abolishes its interaction with
EZH2 and the PRC2 function.55 Whether PLK1 also directly
phosphorylates EZH2 is unknown.
It is worth of mentioning that EZH2 has an influence on
DNA methylation by direct association with DNMTs.92 DNA
methylation abnormal changes can be highly present in
advanced stages of prostate cancer, and changes are tied
together with alterations of EZH2 activity in silencing tumor
suppressors. Thus, if not all, modifications, like PTMs, that
affect EZH2 activity will also affect DNA methylation. For
example, one study has shown that EZH2 directly interacts
with DNMTs and contributes to DNA hypermethylation of
selected target genes (particularly GSTP1 and RARB2) by
qRT-PCR in 47 primary prostate cancers.93 Additionally,
EZH2 and DNMT3B have been shown to mediate
hypermethylation of HOXB13 in prostate cancer cells, and
both EZH2 and DNMT3B could be repressed by an anticancer
agent, all-trans retinoic acid (ATRA) flowing a reduced
methylation of HOXB13.94
Conclusions
PCa is the most commonly diagnosed malignant neoplasm of
males in the United States, and ADT is an effective treat-
ment for patients with PCa. However, most patients ulti-
mately develop resistance and cancer relapse. Treatment
for CRPC is very limited. Therefore, exploring novel cellular
mechanisms controlling progression of PCa is very critical
for identifying new targets and eventually developing effi-
cient strategies to treat CRPC. Expression of EZH2 is often
upregulated in CRPC, thus EZH2 has been proposed as a
target for CRPC. Importantly, it has been demonstrated
that EZH2 becomes hyperphosphorylated in CPRC cells.63
However, very few studies reported the effect of PLK1-
dependent phosphorylation on epigenetic modifications.
Figure 1 The dynamic epigenetic modifications on DNA and histone tail. Enzymes coordinately regulate the epigenetic modifi-
cations by adding or removing epigenetic hallmarks. Deregulation of the enzymes can lead to oncogenesis.
Figure 2 A model of the EZH2 functional switch by its hyper phosphorylation in CRPC. Deregulation of EZH2 phosphorylation can
change EZH2 from a transcriptional repressor depending upon PRC2 to a transcriptional co-activator cooperating with AR which is
independent of PRC2, finally contributing to CRPC progression.
610 R. Wang, X. Liu
Our ongoing study is expected to fill in this knowledge gap
by determining whether and how PLK1-dependent phos-
phorylation of various epigenetic regulators contributes to
PCa progression and drug resistance.
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58. Estève P-O, Chang Y, Samaranayake M, et al. A methylation
and phosphorylation switch between an adjacent lysine and
serine determines human DNMT1 stability. Nat Struct Mol Biol.
2011;18(1):42e48.
59. Li C, Ebert PJR, Li Q-J. T cell receptor (TCR) and transforming
growth factor b (TGF-b) signaling converge on DNA (cytosine-
5)-methyltransferase to control forkhead box protein 3 (foxp3)
locus methylation and inducible regulatory T cell differentia-
tion. J Biol Chem. 2013;288(26):19127e19139.
60. Deplus R, Blanchon L, Rajavelu A, et al. Regulation of DNA
methylation patterns by CK2-mediated phosphorylation of
Dnmt3a. Cell Rep. 2014;8(3):743e753.
61. Cha T-L, Zhou B-P, Xia W, et al. Akt-Mediated phosphorylation
of EZH2 suppresses methylation of lysine 27 in histone H3.
Science. 2005;310(5746):306e310.
62. Bredfeldt TG, Greathouse KL, Safe SH, et al. Xenoestrogen-
induced regulation of EZH2 and histone methylation via es-
trogen receptor signaling to PI3K/AKT. Mol Endocrinol. 2010;
24(5):993e1006.
63. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in
castration-resistant prostate cancer cells is polycomb-inde-
pendent. Science. 2012;338(6113):1465e1469.
64. Wan L, Xu K, Wei Y, et al. Phosphorylation of EZH2 by AMPK
suppresses PRC2 methyltransferase activity and oncogenic
function. Mol Cell. 2018;69(2):279e291.
65. Chen S, Bohrer LR, Rai AN, et al. Cyclin-dependent kinases
regulate epigenetic gene silencing through phosphorylation of
EZH2. Nat Cell Biol. 2010;12(11):1108e1114.
66. Wei Y, Chen YH, Li LY, et al. CDK1-dependent phosphorylation
of EZH2 suppresses methylation of H3K27 and promotes oste-
ogenic differentiation of human mesenchymal stem cells. Nat
Cell Biol. 2011;13(1):87e94.
67. Yan J, Li B, Lin B, et al. EZH2 phosphorylation by JAK3 medi-
ates a switch to noncanonical function in natural killer/T-cell
lymphoma. Blood. 2016;128(7):948e958.
68. Liu H, Takeda S, Kumar R, et al. Phosphorylation of MLL by ATR
is required for execution of mammalian S-phase checkpoint.
Nature. 2010;467(7313):343e346.
69. Liu F, Zhao X, Perna F, et al. JAK2V617F-Mediated phosphory-
lation of PRMT5 downregulates its methyltransferase activity
and promotes myeloproliferation. Cancer Cell. 2011;19(2):
283e294.
70. Baba A, Ohtake F, Okuno Y, et al. PKA-dependent regulation of
the histone lysine demethylase complex PHF2eARID5B. Nat
Cell Biol. 2011;13:668.
71. Arteaga MF, Mikesch JH, Qiu J, et al. The histone demethylase
PHF8 governs retinoic acid response in acute promyelocytic
leukemia. Cancer Cell. 2013;23(3):376e389.
72. Barlev NA, Poltoratsky V, Owen-Hughes T, et al. Repression
of GCN5 histone acetyltransferase activity via
bromodomain-mediated binding and phosphorylation by the
KueDNA-dependent protein kinase complex. 1998;18(3):
1349e1358.
73. Kawasaki H, Schiltz L, Chiu R, et al. ATF-2 has intrinsic histone
acetyltransferase activity which is modulated by phosphory-
lation. Nature. 2000;405:195.
74. Huang W-C, Chen C-C. Akt phosphorylation of p300 at ser-1834
is essential for its histone acetyltransferase and transcriptional
activity. Mol cell biol. 2005;25(15):6592e6602.
75. Seto E, Yoshida M. Erasers of histone acetylation: the histone
deacetylase enzymes. Cold Spring Harbor Perspect Biol. 2014;
6(4):a018713.
76. Williams KA. Phosphorylation of histone deacetylase 6 within
its c-terminal region by extracellular signal regulated kinase
1. Dissertation. University of South Florida; 2013.
77. Citro S, Miccolo C, Meloni L, Chiocca S. PI3K/mTOR mediate
mitogen-dependent HDAC1 phosphorylation in breast cancer: a
novel regulation of estrogen receptor expression. J Mol Cell
Biol. 2015;7(2):132e142.
78. Hanigan TW, Aboukhatwa SM, Taha TY, et al. Divergent JNK
phosphorylation of HDAC3 in triple-negative breast cancer cells
determines HDAC inhibitor binding and selectivity. Cell Chem
Biol. 2017;24(11):1356e1367.
79. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA:
Cancer J Clin. 2019;69(1):7e34.
80. Karantanos T, Corn PG, Thompson TC. Prostate cancer pro-
gression after androgen deprivation therapy: mechanisms of
castrate resistance and novel therapeutic approaches. Onco-
gene. 2013;32(49):5501e5511.
81. Ferraldeschi R, Welti J, Luo J, et al. Targeting the androgen
receptor pathway in castration-resistant prostate cancer:
progresses and prospects. Oncogene. 2015;34:1745e1757.
82. Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S,
Sternberg CN. Enzalutamide for the treatment of metastatic
castration-resistant prostate cancer. Drug Des Dev Ther. 2015;
9:3325e3339.
83. Liu C, Lou W, Zhu Y, et al. Intracrine androgens and AKR1C3
activation confer resistance to enzalutamide in prostate can-
cer. Cancer Res. 2015;75(7):1413e1422.
84. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.
Androgen receptor splice variants mediate enzalutamide
resistance in castration-resistant prostate cancer cell lines.
Cancer Res. 2013;73(2):483e489.
612 R. Wang, X. Liu
85. Kong Y, Cheng L, Mao F, et al. Inhibition of cholesterol
biosynthesis overcomes enzalutamide resistance in castration-
resistant prostate cancer (CRPC). J Biol Chem. 2018;293(37):
14328e14341.
86. Tan J-z, Yan Y, Wang XX, Jiang Y, Xu HE. EZH2: biology, dis-
ease, and structure-based drug discovery. Acta Pharmacol Sin.
2014;35(2):161e174.
87. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt
signaling circuits by the polycomb group protein EZH2 in breast
cancer cells. Mol Cell Biol. 2007;27(14):5105e5119.
88. Lee ST, Li Z, Wu Z, et al. Context-specific regulation of NF-kB
target gene expression by EZH2 in breast cancers. Mol Cell.
2011;43(5):798e810.
89. Gonzalez ME, Moore HM, Li X, et al. EZH2 expands breast stem
cells through activation of NOTCH1 signaling. Proc Natl Acad
Sci. 2014;111(8):3098e3103.
90. Jung H-Y, Jun S, Lee M, et al. PAF and EZH2 induce Wnt/b-
Catenin signaling hyperactivation. Mol Cell. 2013;52(2):
193e205.
91. Li J, Karki A, Hodges KB, et al. Cotargeting polo-like kinase 1 and
the Wnt/b-Catenin signaling pathway in castration-resistant
prostate cancer. Mol Cell Biol. 2015;35(24):4185e4198.
92. Fuks F. DNA methylation and histone modifications: teaming up
to silence genes. Curr Opin Genet Dev. 2005;15(5):490e495.
93. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA.
Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or
DNMT3B are associated with DNA methylation changes in
prostate cancer. Cancer Biol Ther. 2007;6(9):1399e1408.
94. Liu Z, Ren G, Shangguan C, et al. ATRA inhibits the prolifera-
tion of DU145 prostate cancer cells through reducing the
methylation level of HOXB13 gene. PLoS One. 2012;7(7).
e40943.
Regulation of prostate cancer 613
